Literature DB >> 29609965

BCG vaccine: WHO position paper, February 2018 - Recommendations.

.   

Abstract

This article presented the World Health Organization's (WHO) recommendations on the use of on Bacille Calmette-Guérin (BCG) vaccine excerpted from the BCG vaccines: WHO position paper - February 2018 published in the Weekly Epidemiological Record [1]. This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine [2] and the 2007 WHO revised BCG vaccination guidelines for infants at risk for human immunodeficiency virus (HIV) infection [3]. It incorporates recent developments in the tuberculosis (TB) field, provides revised guidance on the immunization of children infected with HIV, and re-emphasizes the importance of the birth dose. This position paper also includes recommendations for the prevention of leprosy. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation tables. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of cholera vaccines were discussed by the Strategic Advisory Group of Experts (SAGE) in October 2017; evidence presented at these meetings can be accessed at: http://www.who.int/immunization/sage/meetings/2017/october/presentations_background_docs/en/.
Copyright © 2018 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bacille Calmette-Guérin; Leprosy; Tuberculosis; Vaccine policy; Vaccines

Mesh:

Substances:

Year:  2018        PMID: 29609965     DOI: 10.1016/j.vaccine.2018.03.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

1.  BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults.

Authors:  Srabanti Rakshit; Asma Ahmed; Vasista Adiga; Bharath K Sundararaj; Pravat Nalini Sahoo; John Kenneth; George D'Souza; Wesley Bonam; Christina Johnson; Kees Lmc Franken; Tom Hm Ottenhoff; Greg Finak; Raphael Gottardo; Kenneth D Stuart; Stephen C De Rosa; M Juliana McElrath; Annapurna Vyakarnam
Journal:  JCI Insight       Date:  2019-12-19

2.  Inborn Errors of Immunity in Patients with Adverse Events Following BCG Vaccination in Brazil.

Authors:  Paula T Lyra; Edvaldo Souza; Ana Carla A Moura; Marina C Matta; Leuridan C Torres; Antonio Victor Campos Coelho; Maria Ângela W Rocha; Luiz Arraes; João Bosco Oliveira
Journal:  J Clin Immunol       Date:  2022-07-30       Impact factor: 8.542

Review 3.  BCG: a vaccine with multiple faces.

Authors:  Marco Antonio Yamazaki-Nakashimada; Alberto Unzueta; Luisa Berenise Gámez-González; Napoleón González-Saldaña; Ricardo U Sorensen
Journal:  Hum Vaccin Immunother       Date:  2020-01-29       Impact factor: 3.452

Review 4.  Research and development of new tuberculosis vaccines: a review.

Authors:  Lewis K Schrager; Rebecca C Harris; Johan Vekemans
Journal:  F1000Res       Date:  2018-11-01

Review 5.  A review of the BCG vaccine and other approaches toward tuberculosis eradication.

Authors:  Thomas Cho; Christopher Khatchadourian; Huy Nguyen; Yash Dara; Shuna Jung; Vishwanath Venketaraman
Journal:  Hum Vaccin Immunother       Date:  2021-03-26       Impact factor: 3.452

6.  Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Authors:  Athina Kilpeläinen; Narcís Saubi; Núria Guitart; Nathifa Moyo; Edmund G Wee; Krupa Ravi; Tomáš Hanke; Joan Joseph
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

7.  The in vitro Mycobacterium bovis BCG Moreau infection of human monocytes that induces Caspase-1 expression, release and dependent cell death is mostly reliant upon cell integrity.

Authors:  Paulo R Z Antas; Carlos G G Ponte; Matheus R Almeida; Lawrence H P Albuquerque; Periela S Sousa-Vasconcelos; Thaíze Pedro; Natália L S Gomes; Otacílio C Moreira; Fernanda C Silva; Luíz R R Castello-Branco; Rosa T Pinho
Journal:  J Inflamm (Lond)       Date:  2019-07-15       Impact factor: 4.981

8.  Case Report: BCG-Triggered Hemophagocytic Lymphohistiocytosis in an Infant With X-Linked Recessive Mendelian Susceptibility to Mycobacterial Disease Due to a Variant of Chronic Granulomatous Disease.

Authors:  Suleiman Al-Hammadi; Amal M Yahya; Abdulla Al-Amri; Amar Shibli; Ghazala B Balhaj; Mohamed I Tawil; Ranjit Vijayan; Abdul-Kader Souid
Journal:  Front Pediatr       Date:  2021-06-29       Impact factor: 3.418

Review 9.  BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.

Authors:  Alok K Singh; Mihai G Netea; William R Bishai
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

10.  Nanomedicines for the Delivery of Biologics.

Authors:  John Wahlich; Arpan Desai; Francesca Greco; Kathryn Hill; Arwyn T Jones; Randall J Mrsny; Gianfranco Pasut; Yvonne Perrie; F Philipp Seib; Leonard W Seymour; Ijeoma F Uchegbu
Journal:  Pharmaceutics       Date:  2019-05-03       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.